D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL)

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $6.00 price target on the stock.

A number of other research analysts also recently weighed in on the company. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Artelo Biosciences in a report on Tuesday, March 4th.

Artelo Biosciences Stock Performance

ARTL opened at $0.86 on Wednesday. The company’s 50-day simple moving average is $1.11 and its two-hundred day simple moving average is $1.11. The stock has a market capitalization of $2.82 million, a P/E ratio of -0.30 and a beta of 1.06. Artelo Biosciences has a 52-week low of $0.86 and a 52-week high of $1.60.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43). Research analysts forecast that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.